SCHEMBL4079762

SCHEMBL4079762

c1ccc2cc(-c3n[nH]c4ccc(-c5n[nH]c(CN6CCCC6)n5)cc34)ccc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.74
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CLK2 P49760 9/20 0.44
DYRK1A Q13627 9/20 0.44
CLK3 P49761 8/20 0.44
GAK O14976 1/20 0.43
DYRK3 O43781 1/20 0.43
JAK2 O60674 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
NQO2 P16083 1/20 0.43
CSNK2A2 P19784 1/20 0.43
FECH P22830 1/20 0.43
JAK1 P23458 1/20 0.43
TYK2 P29597 1/20 0.43
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5387406 0.90 CSNK1D (0.82) CSNK1DKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4084827 0.90 CSNK1D (0.71) CSNK1DCLK2DYRK1ACLK3GAK
SCHEMBL4083423 0.88 CSNK1D (0.66) CSNK1DKDM4EALDH1A1HSD17B10CLK2
SCHEMBL5246773 0.88 CSNK1D (0.68) CSNK1DKDM4EALDH1A1HSD17B10CLK2
SCHEMBL4084738 0.87 CSNK1D (0.65) CSNK1DKDM4EALDH1A1HSD17B10CLK2
SCHEMBL4090371 0.87 CSNK1D (0.67) CSNK1DKDM4EALDH1A1HSD17B10CLK2
SCHEMBL4091542 0.86 CSNK1D (0.66) CSNK1DKDM4EHPGDHSD17B10CLK2
SCHEMBL13877022 0.86 CSNK1D (0.66) CSNK1DCLK2DYRK1ACLK3GAK
SCHEMBL4079722 0.85 CSNK1D (0.60) CSNK1DCLK2DYRK1ACLK3GAK
SCHEMBL13812019 0.85 CSNK1D (0.65) CSNK1DHPGDCLK2DYRK1ACLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885KDM4E 3468/4885ALDH1A1 3165/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885KDM4E 3359/4885ALDH1A1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.